Shannon John Patrick Jr's Form 4 filing
Xeris Biopharma Holdings, Inc. (XERS) · filed Jan 6, 2026
- Accession no.
- 0001553595-26-000002
- Filed
- Jan 6, 2026
- Trade date
- Jan 5, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $176.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shannon John Patrick JrCIK 0001553595 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | SSaleDisposed | −24,907 | $7.08F2 | −$176,341.56 | 2,705,346 | Direct | |
| Jan 5, 2026 | Common Stock | MOption exerciseAcquired | +64,265 | $1.55 | +$99,610.75 | 2,769,611 | Direct | |
| Jan 5, 2026 | Common Stock | MOption exerciseAcquired | +25,136 | $1.55 | +$38,960.8 | 2,794,747 | Direct | |
| Jan 5, 2026 | Common Stock | MOption exerciseAcquired | +2,900 | $3.94 | +$11,426 | 2,797,647 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | MOption exerciseDisposed | −64,265 | $0.00 | $0 | 0 | Direct | |
| Jan 5, 2026 | Common Stock | MOption exerciseDisposed | −25,136 | $0.00 | $0 | 0 | Direct | |
| Jan 5, 2026 | Common Stock | MOption exerciseDisposed | −2,900 | $0.00 | $0 | 97,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.040 to $7.350, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Executive Officer and Director